• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Auris Medical Receives Notice of Allowance for US and European Patent Applications

    Jocelyn Aspa
    Sep. 11, 2019 09:53AM PST
    Biotech Investing

    Auris Medical Holding (NASDAQ:EARS) has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application as well the receipt of an intention to grant notice from the European Patent Office. As quoted in the press release: Upon issuance, the patents are expected to expire no earlier …

    Auris Medical Holding (NASDAQ:EARS) has announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application as well the receipt of an intention to grant notice from the European Patent Office.

    As quoted in the press release:

    Upon issuance, the patents are expected to expire no earlier than February 2038 and will provide key intellectual property protection for the Company’s intranasal betahistine program.

    The allowed claims cover composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery. The communications from the USPTO and EPO conclude substantive examination of the patent applications, which are now expected to issue as patents once the issue fees are paid and the patent offices conclude their respective administrative procedures. Auris Medical also has filed corresponding patent applications that will allow the Company to seek similar patent protection in other key markets throughout the world.

    “We are very pleased to have achieved this major milestone in the protection of our intellectual property around the intranasal betahistine program“, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “The intranasal delivery route allows for a surprisingly strong increase in betahistine concentration in the bloodstream compared to the common oral route, which is expected to result in superior therapeutic benefits. We look forward to developing this innovation further in order to help patients who are suffering from vertigo or antipsychotic-induced weight gain, among other potential medical conditions.”

    Click here to read the full press release.

    european patent officeauris medicalus patent and trademark officenasdaq:ears
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Doctor looking into a microscope

    5 Small Medical Device Companies

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×